Kerry: spying row shouldn't cloud U.S.-EU trade talks

WARSAW Tue Nov 5, 2013 4:39am EST

U.S. Secretary of State John Kerry speaks during a joint news conference with Saudi Foreign Minister Prince Saud al-Faisal (not pictured) in Riyadh November 4, 2013. REUTERS/Faisal Al Nasser

U.S. Secretary of State John Kerry speaks during a joint news conference with Saudi Foreign Minister Prince Saud al-Faisal (not pictured) in Riyadh November 4, 2013.

Credit: Reuters/Faisal Al Nasser

Related Topics

WARSAW (Reuters) - European concerns about alleged electronic eavesdropping by U.S. intelligence should not be allowed to cloud trade talks next week between the United States and the European Union, U.S. Secretary of State John Kerry said on Tuesday.

"This is a trade partnership. It has the ability to lift all of our countries," Kerry said on a visit to Poland. "(It) is really separate from any other issues that people may have on their minds."

European governments have asked Washington for explanations after newspapers printed allegations that the U.S. National Security Agency (NSA) monitored the mobile phones of senior officials, including German Chancellor Angela Merkel.

Negotiators from the United States and Europe are scheduled to start a week of talks in Brussels on November 11 to try to hammer out what will be the world's biggest free-trade deal. It will be the second round of negotiations on the agreement.

Kerry said the deal would create the most powerful marketplaces on the face of the planet.

"Together that can have a profound positive impact to our people, it will put millions of people to work, create new jobs, more opportunities and it is worth pushing for," Kerry said.

"Now that should not be confused with whatever legitimate questions exist with respect to NSA or other issues. We want to hear from our allies, we want to have this conversation."

Referring to the role of intelligence agencies in both Europe and the United States in protecting citizens from threats to their security, Kerry said: "We're all in this together."

Kerry, speaking to reporters alongside his Polish counterpart Radoslaw Sikorski, also said U.S. companies, with government support, would compete vigorously to win major defense contracts being put out to tender by Poland.

He said the U.S. military's plans to set up missile defense facilities in eastern Europe, including Poland, were on track.

A missile defense plan drawn up by a previous U.S. administration angered Russia, prompting U.S. President Barack Obama to reduce the scope of the deployment. After that, Poland sought reassurances that Washington would not back out entirely.

"The plans for missile defense are absolutely on target. We have already, on October 28, broken ground on the phase two, and we intend to provide for the next phase in 2018," Kerry said.

"That is our plan. Nothing has changed in that at this point in time. I don't foresee it changing at this point," Kerry said. "Obviously we will fulfill our obligations and work together with the government of Poland with respect to the deployment."

(Additional reporting by Marcin Goettig; Writing by Christian Lowe)

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (4)
kaceltd wrote:

All that needs to be done by the rest of the world, is sign and stamp the US trade position. Remember, the United States already knows the extent of each country’s wiggle room is.

“Negotiations”, are redundant in the 21st century………..

Nov 05, 2013 4:59am EST  --  Report as abuse
endorendil wrote:
He’s right, though. It shouldn’t cloud them, it should end them.

Nov 05, 2013 8:12am EST  --  Report as abuse
garyvmont wrote:
the trade deal will take high value european prescription drug alternatives “off the table” for huge new profit potentials for american drug companies at the expense of some of the middle class who refuse to pay the exorbitant US drug prices.

Nov 06, 2013 8:25am EST  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.